J.B. Chemicals & Pharmaceuticals Ltd

506943

Overview

    • Equity Style Box

      Mid Growth

    • Sector

      Healthcare

    • Industry

      Drug Manufacturers - Specialty & Generic

    • Day Range

      1,690.05 – 1,748.95

    • Year Range

      1,434.85 – 2,029.00

    • Market Cap

      265.1806 Bil

    • Volume / Avg

      2.0 k / 3.5 k

    • Price / Sales

      7.24

    • Price / Book

      8.34

    • Price / Earnings

      42.91

    • Forward Div Yield

      0.99%

    • Trailing Div Yield

      0.88%

Login To Show Full Chart

Summary

Fair Value Assessment
Overvalued (6% Premium)
Fair ValueQ1,603.19UncertaintyHigh
Close Price1,703.40Mar 26, 2025
Trading Information Business Description
Previous Close
1,703.40
Day Range
1,690.05 – 1,748.95
Year Range
1,434.85 – 2,029.00
Bid / Ask
—
Market Cap
265.2 Bil
Volume / Average
2.0 k / 3.5 k
Beta (5-Year)
0.23
Shares Outstanding
155.68 Mil
Primary Exchange
Bombay Stock Exchange

Business Description
J.B. Chemicals & Pharmaceuticals Ltd is an India-based pharmaceutical company. It manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs). The company's products include various pharmaceutical dosage forms like tablets, injectable, creams, ointments, lozenges, herbal liquids, and capsules. It also offers services including optimization of formulations, scale-up services, stability testing, regulatory support, packaging design, and commercial production. The group derives revenue from the manufacturing and marketing of a diverse range of pharmaceutical products. The company sells its products in India and also exports them to other international countries.
Contact
Appa Saheb Marathe Marg Cnergy IT Park, Mumbai, MH 400 025
T +91 2224395200
www.jbpharma.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
7,386
As of Mar 31, 2024

Key Metrics

Income Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
37.94 34.48 31.49 24.09 20.02 17.41
Revenue Growth %
13.18% 10.63% 29.91% 19.33% 14.98% 8.32%
Gross Profit
24.78 22.45 19.81 15.46 12.85 10.87
Gross Profit Margin %
65.31% 65.11% 62.91% 64.16% 64.17% 62.43%
Operating Income
8.32 7.53 5.81 4.75 4.87 3.18
Operating Margin %
21.94% 21.83% 18.46% 19.70% 24.34% 18.26%
EBIT
8.74 7.91 5.91 5.09 6.02 3.49
EBIT Margin %
23.03% 22.94% 18.78% 21.12% 30.07% 20.04%
EBITDA
10.39 9.29 7.06 5.81 6.71 4.15
EBITDA Margin %
27.38% 26.95% 22.41% 24.13% 33.50% 23.85%
Net Income
6.40 5.53 4.10 3.85 4.48 2.72
Net Profit Margin %
16.87% 16.03% 13.02% 16.02% 22.40% 15.64%
Basic EPS
41.22 35.66 26.50 24.93 28.98 17.10
Diluted EPS
40.22 34.85 26.17 24.91 28.98 17.10
Normalized EPS
41.78 35.63 30.75 29.96 25.05 15.92
Total Dividends per Share
12.25 10.13 8.25 8.25 4.75 7.50
Balance Sheet (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
40.29 39.94 35.54 26.07 22.38 18.14
Total Liabilities
8.17 10.71 10.74 4.69 4.25 3.76
Total Debt
1.00 3.78 5.72 0.55 0.45 0.38
Total Equity
32.12 29.23 24.80 21.39 18.13 14.38
Cash And Cash Equivalents
0.90 0.88 0.77 0.57 0.29 0.29
Working Capital
12.91 9.85 9.74 8.91 12.07 7.60
Shares Outstanding (Bil)
— — — 0.15 — —
Book Value Per Share
— 179.35 160.28 134.02 117.09 92.87
Total Debt To Equity
0.03 0.13 0.23 0.03 0.02 0.03
Cash Flow Statement (in Bil, except ratios)
09/30/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
7.57 8.01 6.26 1.70 3.15 2.75
Cash From Investing Activities
-2.02 -4.04 -9.62 0.02 -2.31 0.24
Cash From Financing Activities
-5.57 -3.85 3.57 -1.38 -0.87 -3.06
Capital Expenditures
— 2.61 7.65 7.07 0.48 0.73
Free Cash Flow
— 5.01 -1.42 -2.37 3.55 1.91
Change in Cash
-0.02 0.11 0.20 0.34 -0.03 -0.06

Profile

Name (Age)
5-Year Trend
2021
2022
2023
2024
2025
Nikhil Ashok kumar Chopra (—) Director and Chief Executive Officer — — — — — —
Total Compensation for all Key Executives — — — — — —
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership


STOCKS
MUTUAL FUNDS
ADITYABIRLAAXISBajajBANDHANBARODABNPBOICANARADSPEDELWEISSFRANKLINTEMPLETONGROWWHDFCHELIOSHSBCICICIIIFLINVESCOITIJMKOTAKLICMahindraManulifeMIRAEMOTILALNAVINipponNJOldBridgePGIMPPFASQUANTQUANTUMSAMCOSBISHRIRAMSUNDARAMTATATAURUSTrustUNIONUTIWhiteOakZERODHA
INSURANCE FUNDS
ABSLAEGONAGEASFEDERALAVIVABAJAJALLIANZBHARTIAXACANARAHSBCORIENTBANKEDELWEISSTOKIOEXIDEFUTUREGENERALIHDFCICICIPRUDENTIALINDIAFIRSTKOTAKMAHINDRALICMAXLIFEPNBMETLIFEPRAMERICARELIANCENIPPONSAHARASBISHRIRAMSTARUNIONDAI-ICHITATAAIA

About Us

Connect With Us

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top